"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 5 | 5 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 5 | 7 |
| 2015 | 5 | 3 | 8 |
| 2016 | 2 | 0 | 2 |
| 2017 | 7 | 3 | 10 |
| 2018 | 1 | 1 | 2 |
| 2019 | 4 | 2 | 6 |
| 2020 | 4 | 1 | 5 |
| 2021 | 0 | 4 | 4 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Risk factors associated with mortality in individuals with type 2 diabetes following an episode of severe hypoglycaemia. Results from a randomised controlled trial. Diab Vasc Dis Res. 2022 Jan-Feb; 19(1):14791641211067415.
-
Application of Machine Learning to Assess Interindividual Variability in Rapid-Acting Insulin Responses After Subcutaneous Injection in People With Type 1 Diabetes. Can J Diabetes. 2022 Apr; 46(3):225-232.e2.
-
Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer. Adv Drug Deliv Rev. 2021 11; 178:113918.
-
Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021 07 29; 385(5):416-426.
-
A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. Endocrinol Diabetes Metab. 2021 Jul; 4(3):e00237.
-
Adjunct therapies in treatment of type 1 diabetes. J Diabetes. 2020 Oct; 12(10):742-753.
-
Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial. Cardiovasc Diabetol. 2020 08 12; 19(1):127.
-
Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications. Future Med Chem. 2020 07; 12(14):1327-1358.
-
Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. Catheter Cardiovasc Interv. 2020 08; 96(2):298-308.
-
Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome? Fertil Steril. 2020 01; 113(1):87-88.